Corrigendum: Enhanced cytotoxic effects of combined valproic acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer cells [Front Oncol., 3, (2013), 58.] Doi: 10.3389/fonc.2013.00058;Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Li, Yanfang ^a,b   Liu, Tao ^a   Ivan, Cristina ^a   Huang, Jie ^a   Shen, De Yu ^a   Kavanagh, John J ^a   Bast, Robert C ^a   Fu, Siqing ^a   Hu, Wei ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Aurora kinase inhibitor; Cervical cancer; Endometrial cancer; Ovarian cancer; Valproic acid

Indexed keywords

AURORA KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; UNCLASSIFIED DRUG; VALPROIC ACID; VE 465;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPIGENETICS; FLOW CYTOMETRY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; NICK END LABELING; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84885802146     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2018.00009     Document Type: Erratum

References (47)

1. Adams, R. R., Carmena, M., and Earnshaw, W. C. (2001). Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 11, 49-54.
2. Balch, C., Huang, T. H., Brown, R., and Nephew, K. P. (2004). The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 191, 1552-1572.
3. Benedet, J. L., Odicino, F., Maisonneuve, P., Beller, U., Creasman, W. T., Heintz, A. P., et al. (2001). Carcinoma of the cervix uteri. J. Epidemiol. Biostat. 6, 7-43.
4. Blaheta, R. A., Michaelis, M., Driever, P. H., and Cinatl, J. Jr. (2005). Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Med. Res. Rev. 25, 383-397.
5. Carvajal, R. D., Tse, A., and Schwartz, G. K. (2006). Aurora kinases: New targets for cancer therapy. Clin. Cancer Res. 12, 6869-6875.
6. Caslini, C., Capo-Chichi, C. D., Roland, I. H., Nicolas, E., Yeung, A. T., and Xu, X. X. (2006). Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25, 5446-5461.
7. Chou, T. C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681.
8. Chou, T. C. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446.
9. Cress, W. D., and Seto, E. (2000). Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184, 1-16.
10. de la Cruz-Hernandez, E., Perez-Cardenas, E., Contreras-Paredes, A., Cantu, D., Mohar, A., Lizano, M., et al. (2007). The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol. J. 4, 18.
11. Facchetti, F., Previdi, S., Ballarini, M., Minucci, S., Perego, P., and La Porta, C. A. (2004). Modulation of pro-and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9, 573-582.
12. Fancelli, D., Berta, D., Bindi, S., Cameron, A., Cappella, P., Carpinelli, P., et al. (2005). Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. 48, 3080-3084.
13. Fancelli, D., Moll, J., Varasi, M., Bravo, R., Artico, R., Berta, D., et al. (2006). 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 49, 7247-7251.
14. Fu, S., Hu, W., Kavanagh, J. J., and Bast, R. C. Jr. (2006). Targeting Aurora KINASES in ovarian cancer. Expert Opin. Ther. Targets 10, 77-85.
15. Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., et al. (2006). Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108, 3271-3279.
16. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978.
17. Gritsko, T. M., Coppola, D., Paciga, J. E., Yang, L., Sun, M., Shelley, S. A., et al. (2003). Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin. Cancer Res. 9, 1420-1426.
18. Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. Nature 389, 349-352.
19. Gurvich, N., Tsygankova, O. M., Meinkoth, J. L., and Klein, P. S. (2004). Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64, 1079-1086.
20. Hickerson, J. W. (2003). Endometrial carcinoma: Treatment and outcomes in the regional hospital setting. Am. J. Obstet. Gynecol. 188, 1573-1577; discussion 1577-1578.
21. Hrzenjak, A., Moinfar, F., Kremser, M. L., Strohmeier, B., Staber, P. B., Zatloukal, K., et al. (2006). Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 5, 2203-2210.
22. Hu, W., Kavanagh, J. J., Deaver, M., Johnston, D. A., Freedman, R. S., Verschraegen, C. F., et al. (2005). Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol. Res. 15, 49-57.
23. Hu, W., Verschraegen, C. F., Wu, W. G., Nash, M., Freedman, R. S., Kudelka, A., et al. (2002). Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int. J. Gynecol. Cancer 12, 202-207.
24. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M. J. (2007). Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66.
25. Li, X., Sakashita, G., Matsuzaki, H., Sugimoto, K., Kimura, K., Hanaoka, F., et al. (2004). Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J. Biol. Chem. 279, 47201-47211.
26. Li, X. N., Shu, Q., Su, J. M., Perlaky, L., Blaney, S. M., and Lau, C. C. (2005). Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther. 4, 1912-1922.
27. Lin, Y. G., Immaneni, A., Merritt, W. M., Mangala, S. L., Kim, S. W., Armaiz-Pena, G. N., et al. (2008). Aurora kinase targeting inhibits tumor growth in ovarian cancer. Clin. Cancer Res. 14, 5437-5446.
28. Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., et al. (2005). Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Med. Res. Rev. 25, 261-309.
29. Marks, P. A., Richon, V. M., and Rifkind, R. A. (2000). Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216.
30. Marth, C., Daxenbichler, G., and Dapunt, O. (1986). Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J. Natl. Cancer Inst. 77, 1197-1202.
31. Melichar, B., Patenia, R., Gallardo, S., Melicharova, K., Hu, W., and Freedman, R. S. (2007). Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol. Oncol. 104, 707-713.
32. Moreno-Bueno, G., Sanchez-Estevez, C., Cassia, R., Rodriguez-Perales, S., Diaz-Uriarte, R., Dominguez, O., et al. (2003). Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 63, 5697-5702.
33. Naruganahalli, K. S., Lakshmanan, M., Dastidar, S. G., and Ray, A. (2006). Therapeutic potential of Aurora kinase inhibitors in cancer. Curr. Opin. Investig. Drugs 7, 1044-1051.
34. O'Malley, C. D., Cress, R. D., Campleman, S. L., and Leiserowitz, G. S. (2003). Survival of Californian women with epithelial ovarian cancer, 1994-1996: A population-based study. Gynecol. Oncol. 91, 608-615.
35. Pandolfi, P. P. (2001). Transcription therapy for cancer. Oncogene 20, 3116-3127.
36. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., and Klein, P. S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741.
37. Richon, V. M., and O'Brien, J. P. (2002). Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8, 662-664.
38. Sasai, K., Katayama, H., Stenoien, D. L., Fujii, S., Honda, R., Kimura, M., et al. (2004). Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton 59, 249-263.
39. Saxena, A., Yashar, C., Taylor, D. D., and Gercel-Taylor, C. (2005). Cellular response to chemotherapy and radiation in cervical cancer. Am. J. Obstet. Gynecol. 192, 1399-1403.
40. Smith, J. A., Brown, J., Martin, M. C., Ramondetta, L. M., and Wolf, J. K. (2004). An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol. Oncol. 92, 314-319.
41. Takai, N., Desmond, J. C., Kumagai, T., Gui, D., Said, J. W., Whittaker, S., et al. (2004a). Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10, 1141-1149.
42. Takai, N., Kawamata, N., Gui, D., Said, J. W., Miyakawa, I., and Koeffler, H. P. (2004b). Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101, 2760-2770.
43. Timmermann, S., Lehrmann, H., Polesskaya, A., and Harel-Bellan, A. (2001). Histone acetylation and disease. Cell. Mol. Life Sci. 58, 728-736.
44. Verdin, E., Dequiedt, F., and Kasler, H. G. (2003). Class II histone deacetylases: Versatile regulators. Trends Genet. 19, 286-293.
45. Wheatley, S. P., Henzing, A. J., Dodson, H., Khaled, W., and Earnshaw, W. C. (2004). Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J. Biol. Chem. 279, 5655-5660.
46. Yang, H., He, L., Kruk, P., Nicosia, S. V., and Cheng, J. Q. (2006). Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int. J. Cancer 119, 2304-2312.
47. Zhou, H., Kuang, J., Zhong, L., Kuo, W. L., Gray, J. W., Sahin, A., et al. (1998). Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20, 189-193.